DGCI begins probe into ‘illegal' clinical trials at VS Hospital
SLUG: CENTRAL AGENCY BEGINS PROBEAhmedabad: A team from the regional office of the Drugs Controller General of India (DCGI) made its first visit to VS Hospital on Monday and initiated a probe into allegations of illegal clinical trials there. The team also visited the Ahmedabad Municipal Corporation (AMC).This development follows allegations involving 58 such clinical trials at VS Hospital. During their visit, the DCGI officials reportedly shared details with a senior AMC official.The senior AMC official revealed to TOI that the inspecting DCGI team stated they "never recalled conducting routine inspections at the VS Hospital clinical trial site over the past four years." This comes despite the significant number of 'unauthorised' trials alleged to have taken place during this period. The senior AMC official further said, "We were told by the DCGI that they never visited VS Hospital as a clinical site, but used to frequent the neighbouring SVP Hospital clinical trial site, which had its own Institutional Ethics Committee (IEC) and were aware of the subjects and drug trials being conducted there."The Supreme Court's intervention on April 30, prompted by a petition from the NGO Swasthya Adhikar Manch (SAM) concerning the alleged irregularities at VS Hospital, appears to have spurred the DCGI's current action. "We supplied a copy of our enquiry committee report to the DCGI, including the action taken by the civic body, the details of the financial transactions, and the action taken against doctors who participated in the alleged illegal trials," the senior AMC official informed TOI.Interestingly, Rajshri Kesari, the municipal councillor who initially brought the issue to the forefront, revealed, "I was not approached by the DCGI team."The DCGI's investigation is set to cover crucial aspects of the clinical trials. The AMC official outlined the scope of the probe, stating, "The DCGI inspection team will review the informed consent forms and documentation of the trial subjects and their rights and safety." Also, the ethical oversight mechanisms employed will be examined. "Another crucial aspect of the investigation is the choice of a private ethics committee outside the VS Hospital campus, while neighbouring SVP Hospital had an ethics committee in place," the AMC official pointed out, indicating that the rationale and implications of this arrangement are likely to be scrutinised.The DCGI's mandate to ensure adherence to ethical and regulatory guidelines will guide their investigation. "The DCGI will also examine study protocols, CRFs, and source documents to ensure trial activities align with approved protocols and regulatory standards," the AMC official explained."The DCGI checks whether there was conformity with Good Clinical Practices (GCP) guidelines and the New Drugs and Clinical Trials Rules, 2019. Also, it compares sponsor-submitted data with site source documents to ensure data integrity, especially during post-trial or for-cause inspections."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
an hour ago
- Business Standard
Glenmark Pharma rises after zanubrutinib launch in India
Glenmark Pharmaceuticals rose 1% to Rs 1605.80 after the drug maker announced the upcoming launch of zanubrutinib in India, following approval from the Drugs Controller General of India (DCGI). Co-developed with global oncology leader BeOne Medicines, zanubrutinib will be marketed under the brand name Brukinsa. It is the first and only Brutons tyrosine kinase (BTK) inhibitor approved in India for five types of B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenstr macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and follicular lymphoma (FL). Globally, Brukinsa is approved in over 70 countries, backed by robust clinical evidence from pivotal trials such as Alpine, Aspen, and Sequoia. The drug has shown a strong safety profile, high response rates, and durable disease control. With one Indian diagnosed with blood cancer every five minutes and around 70,000 deaths annually, Brukinsa addresses a critical treatment gap. Its flexible dosing (once or twice daily) supports personalized care. In the Alpine study for relapsed/refractory CLL, Brukinsa reported significantly fewer serious cardiac events (1.9% vs 7.7%) and lower treatment discontinuation (0.3% vs 4.3%) compared to ibrutinib. Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. On a consolidated basis, Glenmark Pharmaceuticals reported net profit of Rs 4.65 crore in Q4 March 2025 as against net loss of Rs 1218.28 crore in Q4 March 2024. Net sales rose 6.77% year-on-year to Rs 3220.13 crore in Q4 March 2025.
Business Standard
2 hours ago
- Business Standard
Glenmark receives DCGI approval to launch oncology drug BRUKINSA in India
Glenmark Pharmaceuticals has announced the upcoming launch of zanubrutinib in India following approval by the Drugs Controller General of India (DCGI). Zanubrutinib will be marketed in India under the brand name BRUKINSA, an innovative therapy developed by BeiGene (now BeOne Medicines), a global oncology leader committed to delivering advanced treatments for cancer patients worldwide. BRUKINSA is the first and only Bruton's tyrosine kinase (BTK) inhibitor approved in India for the treatment of five distinct B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenstr macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and follicular lymphoma (FL). Globally, BRUKINSA is approved in more than 70 countries, supported by compelling clinical evidence from pivotal trials including ALPINE, ASPEN, and SEQUOIA. This extensive clinical program underscores BRUKINSA's proven efficacy, strong safety profile, and broad therapeutic value. The introduction of BRUKINSA brings an innovative treatment option at a time when India continues to face a significant burden from serious and difficult-to-treat haematological malignancies. According to various sources, someone in India is diagnosed with blood cancer every five minutes, and an estimated 70,000 people die from the disease each year. BRUKINSA addresses a critical unmet need with its differentiated pharmacological profile, demonstrating high response rates and durable disease control across multiple B-cell malignancies as shown in pivotal clinical trials. BRUKINSA's flexible dosing regimen (once or twice daily) supports personalized care.1 In the head-to-head ALPINE study in relapsed/refractory chronic lymphocytic leukemia, BRUKINSA demonstrated a lower rate of serious cardiac events (1.9% vs. 7.7%) and fewer treatment discontinuations due to cardiac issues (0.3% vs. 4.3%) compared with ibrutinib.
Indian Express
3 days ago
- Indian Express
India has to maintain global regulatory standards to remain the pharmacy of the world: Ex DCGI
Former Drugs Controller General of India (DCGI) Dr G N Singh, who is now the Advisor to Uttar Pradesh Chief Minister Yogi Adityanath, was leading an outreach programme in Gujarat for pharmaceutical companies to set up units of the Bulk Drug Pharma Park coming up in Lalitpur district. He spoke to The Indian Express on the sidelines of the country's need to maintain global scientific standards and regulation. Dr Singh also served as the Central Drug Standards Control Organisation (CDSCO) for six years till 2018, and as the Founder-Director of the Indian Pharmacopeia Commission (IPC). Excerpts from the interview: How do you see the development and future of the pharmaceutical manufacturing sector in India? India wants to become self reliant in manufacturing and innovation in bulk drugs. That is why the Prime Minister, over the last few years, has given special emphasis on developing pharma parks across the country. In this context, the UP Chief Minister decided to develop a bulk drug park in his state. And we want to make sure that if any international incident happens, since the geopolitical situation is in a troublesome phase, then we can be self-reliant. In such cases, India has to be ready to address issues like healthcare. We (India) are known as the pharmacy of the world since we supply medicines to more than 200 countries. So we have to see that the continuity of supply of medicines remains undisturbed. When you talk about the geopolitical situation, are you referring to the excessive imports of Active Pharmaceutical Ingredients (APIs) from China? Majority of our APIs are being imported from China. It is the thinking of experts at the highest level that India has to be fully self-reliant. We are, but due to cost prohibition, we were lacking in API production. Now with bulk drug parks coming up, the cost of production will also come down and we will become competitive in the international market and hopefully begin supplying APIs to many others, especially Europe and other developed markets. We will capture those markets based on quality, prices and uninterrupted supply. There have been complaints coming in from many nations, including Africa and Europe and ones flagged by the USFDA, regarding the quality of drugs going out from India. How do you see this in context of the way 'made-in-India' medicines are perceived abroad? As scientific systems are developing, the regulatory landscape is also changing. We are continuously adjusting the regulatory system so that the regulator meets the expectations of scientific rigour and the people. Safety, efficacy and quality of medicines is of paramount importance to the regulator and to end users everywhere. So, we want to make a harmonised approach so none of the issues lag behind the science requirements. Both the Drugs and Cosmetics Rules and the Indian Pharmacopeia (IP), which is the book of standards for drugs, are continously being upgraded to address these issues. So, does the Indian drug regulator need more teeth? Is stricter regulation required today? The requirement is to strengthen the drug regulatory system in terms of science, in terms of manpower, in terms of the execution of mechanism and the government must be thinking on those lines because it is aware of these issues. If we want to remain the pharmacy of the world we need to maintain the standards of global science and regulation. The most recent debate is regarding generic drugs. There have been problems highlighted with regards to bioequivalence studies and doctors are pushing back against compulsorily prescribing them. How do you see this issue? It is only a myth. These issues have been raised multiple times and as a scientist, I am of the firm opinion that the book of standards is the same for branded, branded-generic or generic medication. If you take the Indian, US and UK Pharmacopeias, they are not ascribing different standards. They are all the same — right from manufacturing systems, quality control and testing before batches reach the market. So, I don't agree that generic drugs are in any way less than the branded medicines and it is just a myth with no basis in scientific parameters. They are almost equal in my opinion and I had made it very clear on various forums, including international ones, not just as a former drug regulator of this country, but also as the head of the Indian Pharmacopeia Commission. I appeal to the doctors and to the people to accept generic medicines as ones at par with the branded ones.
